GoodRx (NASDAQ:GDRX) Stock Price Up 2% – Should You Buy?

GoodRx Holdings, Inc. (NASDAQ:GDRX) shares traded up 2% on Friday . The stock traded as high as $4.64 and last traded at $4.61. 294,790 shares traded hands during mid-day trading, a decline of 79% from the average session volume of 1,417,572 shares. The stock had previously closed at $4.52.

Analysts Set New Price Targets

GDRX has been the topic of a number of research analyst reports. Barclays cut their price objective on shares of GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a research report on Monday, November 11th. Morgan Stanley reduced their price objective on GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a research note on Tuesday, December 17th. Mizuho started coverage on GoodRx in a report on Wednesday, December 4th. They set a “neutral” rating and a $5.00 price objective for the company. Finally, Citigroup cut their target price on GoodRx from $10.00 to $7.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $8.37.

GoodRx Price Performance

The business’s 50-day simple moving average is $5.09 and its two-hundred day simple moving average is $6.82. The stock has a market cap of $1.76 billion, a P/E ratio of -154.00, a price-to-earnings-growth ratio of 3.54 and a beta of 1.29. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70.

Hedge Funds Weigh In On GoodRx

Large investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. grew its holdings in GoodRx by 358.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 24,293 shares of the company’s stock valued at $169,000 after buying an additional 18,997 shares in the last quarter. Franklin Resources Inc. bought a new position in shares of GoodRx in the third quarter valued at approximately $5,675,000. Sanctuary Advisors LLC purchased a new position in GoodRx during the third quarter valued at approximately $85,000. Barclays PLC increased its holdings in GoodRx by 1,316.1% during the 3rd quarter. Barclays PLC now owns 140,113 shares of the company’s stock worth $973,000 after acquiring an additional 130,219 shares during the period. Finally, Fortem Financial Group LLC bought a new stake in GoodRx during the 3rd quarter worth approximately $772,000. 63.77% of the stock is owned by institutional investors.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.